MarketPulse

Phase 3

7 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Oculis Holding Ag

Oculis to Showcase Late-Stage Pipeline at ARVO 2026 Amid Key DME Trial Readout

Oculis will present its ophthalmology pipeline at ARVO 2026, with Phase 3 results for lead DME candidate OCS-01 expected in June.
OCSOCSAWclinical trialsdiabetic macular edema
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Lexicon Advances Pain Drug After Positive Phase 2b Results

Lexicon Pharmaceuticals' pilavapadin shows promise in diabetic neuropathic pain study, supporting 10mg dose selection for Phase 3 trials.
LXRXclinical trialPhase 3
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Grace Therapeutics' GTx-104 Meets Primary Endpoint in Pivotal aSAH Trial

Grace Therapeutics reports STRIVE-ON Phase 3 trial success for GTx-104, reducing hypotension and improving outcomes in aneurysmal subarachnoid hemorrhage patients versus oral nimodipine.
GRCEclinical trial resultsGTx-104
BenzingaBenzinga··Vandana Singh

United Therapeutics Surges 16.5% on Positive Lung Disease Trial Results

United Therapeutics stock surges 16.5% after TETON-1 Phase 3 study shows Tyvaso meets primary endpoint in lung fibrosis treatment, with priority FDA review expected by summer 2026.
UTHRFDA approvalclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Zealand Pharma

Zealand Pharma's Petrelintide Shows Promise in Obesity Drug Race

Zealand Pharma reports positive Phase 2 data for petrelintide, achieving 10.7% weight loss versus 1.7% placebo with favorable safety profile.
RHHBYZLDPYobesityweight management
BenzingaBenzinga··Business Wire

Savara to Present MOLBREEVI Progress at Miami Life Sciences Conference

Clinical-stage biotech $SVRA will present at 2026 Citizens Life Sciences Conference, showcasing progress on its Phase 3 rare respiratory disease program.
SVRAclinical-stagebiopharmaceutical
BenzingaBenzinga··Vandana Singh

Eli Lilly's Retevmo Shows Significant Benefit in Early-Stage Lung Cancer Trial

Eli Lilly's Retevmo shows significant benefits in early-stage lung cancer, reducing recurrence risk in Phase 3 trial. Positive results may expand the drug's use beyond advanced-stage disease.
LLYclinical triallung cancer